Page last updated: 2024-10-22

anastrozole and Embolus

anastrozole has been researched along with Embolus in 1 studies

Research Excerpts

Excerpt	Relevance	Reference
"Compared with tamoxifen, anastrozole treatment provided a significant improvement in breast cancer-free interval, mainly in women younger than 60 years of age."	5.22	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Margolese, RG	1
Cecchini, RS	1
Julian, TB	1
Ganz, PA	1
Costantino, JP	1
Vallow, LA	1
Albain, KS	1
Whitworth, PW	1
Cianfrocca, ME	1
Brufsky, AM	1
Gross, HM	1
Soori, GS	1
Hopkins, JO	1
Fehrenbacher, L	1
Sturtz, K	1
Wozniak, TF	1
Seay, TE	1
Mamounas, EP	1
Wolmark, N	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy[NCT00053898]	Phase 3	3,104 participants (Actual)	Interventional	2003-01-31	Completed
Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.[NCT03002766]	Phase 2	224 participants (Actual)	Interventional	2000-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Patients Alive (Overall Survival)

Percentage of patients alive. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	92.1
Group 2: Anastrozole + Tamoxifen Placebo	92.5

Percentage of Patients Alive and Disease-free

Percentage of patients free from a disease-free survival event where events include any recurrence, second primary cancer, and death from any cause. Lobular carcinoma in situ (LCIS), basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, and cervical carcinoma in situ will not be included as recurrences or second primary cancer. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	77.9
Group 2: Anastrozole + Tamoxifen Placebo	82.7

Percentage of Patients Free From Breast Cancer

Percentage of patients free from breast cancer event at 10 years where events include local, regional, or distant recurrence or contralateral breast cancer, invasive or DCIS. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	89.1
Group 2: Anastrozole + Tamoxifen Placebo	93.1

Percentage of Patients Free From Contralateral Breast Cancer

Percentage of patients free from a breast cancer recurrence in the contralateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	94.7
Group 2: Anastrozole + Tamoxifen Placebo	97.0

Percentage of Patients Free From Invasive Breast Cancer

Percentage of patients free from an invasive breast cancer event where events include invasive local, regional, or distant recurrence, or contralateral breast cancer, occurring as a first cancer event. Note that this endpoint includes only invasive breast cancers and the primary endpoint includes both invasive and DCIS breast cancers. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	93.3
Group 2: Anastrozole + Tamoxifen Placebo	96.4

Percentage of Patients Free From Ipsilateral Recurrence

Percentage of patients free from a breast cancer recurrence in the ipsilateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	94.6
Group 2: Anastrozole + Tamoxifen Placebo	96.4

Percentage of Patients Free From Non-breast Secondary Cancer

Percentage of patients free from any non-breast second primary cancer other than squamous or basal cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, or carcinoma in situ of the cervix, occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	91.5
Group 2: Anastrozole + Tamoxifen Placebo	91.9

Percentage of Patients Free From Osteoporotic Fractures

Percentage of patients free from fractures of the hip, spine, and wrist. (NCT00053898)
Timeframe: 10 years

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	96.0
Group 2: Anastrozole + Tamoxifen Placebo	95.3

Quality of Life-Short Form 12 (SF-12) Physical Health Component Score

The primary outcome of the QOL substudy was the Medical Outcomes Study-Short Form 12 (SF-12) physical health component scale score. The SF-12 physical score was calculated to have a range of 0-100 and was normalized to have a mean of 50 and a standard deviation of 10 in the general population. Higher scores indicate better health. (NCT00053898)
Timeframe: 5 years

Intervention	units on a scale (Mean)
Group 1: Tamoxifen + Anastrozole Placebo	46.20
Group 2: Anastrozole + Tamoxifen Placebo	45.38

Quality-adjusted Survival Time

The mean quality-adjusted survival time (in months) in each treatment group, estimated by the Quality-Adjusted Time without Symptoms and Toxicity (Q-TWIST) method. (NCT00053898)
Timeframe: 10 years

Intervention	months (Mean)
Group 1: Tamoxifen + Anastrozole Placebo	104.4
Group 2: Anastrozole + Tamoxifen Placebo	102.9

Trials

1 trial available for anastrozole and Embolus

Article	Year
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021 Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor	2016
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021 Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor	2016
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021 Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor	2016
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021 Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor	2016